SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J.-i. Kira, Evidence for efficacy of a drug widely used without authorisation in multiple sclerosis: mycophenolate mofetil, Journal of Neurology, Neurosurgery & Psychiatry, 2014, 85, 3, 246

    CrossRef

  2. 2
    L. Michel, S. Vukusic, J. De Seze, F. Ducray, J. C. Ongagna, F. Lefrere, M. Jacq-Foucher, C. Confavreux, S. Wiertlewski, D. A. Laplaud, Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients, Journal of Neurology, Neurosurgery & Psychiatry, 2014, 85, 3, 279

    CrossRef

  3. 3
    Darin T. Okuda, Multiple Sclerosis and Related Disorders, 2014,

    CrossRef

  4. 4
    Dimitrios Karussis, Immunotherapy of Multiple Sclerosis, BioDrugs, 2013, 27, 2, 113

    CrossRef

  5. 5
    James M. Stankiewicz, Hadar Kolb, Arnon Karni, Howard L. Weiner, Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis, Neurotherapeutics, 2013, 10, 1, 77

    CrossRef

  6. 6
    Naveen Mulakayala, Pallavi Rao, Javed Iqbal, Rakeshwar Bandichhor, Srinivas Oruganti, Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview, European Journal of Medicinal Chemistry, 2013, 60, 170

    CrossRef

  7. 7
    Ron Milo, Hillel Panitch, Combination therapy in multiple sclerosis, Journal of Neuroimmunology, 2011, 231, 1-2, 23

    CrossRef

  8. 8
    Peter Wipfler, Andrea Harrer, Georg Pilz, Katrin Oppermann, Eugen Trinka, Jörg Kraus, Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options, Drug Discovery Today, 2011, 16, 1-2, 8

    CrossRef

  9. 9
    Nancy L Kuntz, Dorothee Chabas, Bianca Weinstock-Guttman, Tanuja Chitnis, E Ann Yeh, Lauren Krupp, Jayne Ness, Moses Rodriguez, Emmanuelle Waubant, Treatment of multiple sclerosis in children and adolescents, Expert Opinion on Pharmacotherapy, 2010, 11, 4, 505

    CrossRef

  10. 10
    S. Schwarz, H.-M. Meinck, B. Storch-Hagenlocher, Intravenöse Immunglobuline bei Multipler Sklerose, Der Nervenarzt, 2009, 80, 8, 918

    CrossRef

  11. 11
    Benjamin M. Greenberg, John N. Ratchford, Peter A. Calabresi, Pharmacology and Therapeutics, 2009,

    CrossRef

  12. 12
    Rocio S. Lopez-Diego, Howard L. Weiner, Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary, Nature Reviews Drug Discovery, 2008, 7, 11, 909

    CrossRef

  13. 13
    Oliver Neuhaus, Bernd C. Kieseier, Hans-Peter Hartung, Immunosuppressive agents in multiple sclerosis, Neurotherapeutics, 2007, 4, 4, 654

    CrossRef

  14. 14
    Jodie M. Burton, Paul O’Connor, Novel oral agents for multiple sclerosis, Current Neurology and Neuroscience Reports, 2007, 7, 3, 223

    CrossRef

  15. 15
    Bernd C Kieseier, Heinz Wiendl, Oral Disease-Modifying Treatments for Multiple Sclerosis, CNS Drugs, 2007, 21, 6, 483

    CrossRef

  16. 16
    James M. Stankiewicz, Samia J. Khoury, Medication Treatment in Multiple Sclerosis,
  17. 17
    Yousheng Xiao, Jianyi Huang, Hongye Luo, Jin Wang, Mycophenolate mofetil for relapsing-remitting multiple sclerosis, The Cochrane Library,
  18. 18
    Yousheng Xiao, Jianyi Huang, Hongye Luo, Jin Wang, Mycophenolate mofetil for relapsing-remitting multiple sclerosis, The Cochrane Library,